首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   5777篇
  免费   523篇
  国内免费   60篇
耳鼻咽喉   46篇
儿科学   116篇
妇产科学   175篇
基础医学   411篇
口腔科学   212篇
临床医学   1032篇
内科学   913篇
皮肤病学   41篇
神经病学   180篇
特种医学   98篇
外国民族医学   1篇
外科学   422篇
综合类   936篇
一般理论   4篇
预防医学   1026篇
眼科学   81篇
药学   373篇
  3篇
中国医学   122篇
肿瘤学   168篇
  2024年   12篇
  2023年   213篇
  2022年   189篇
  2021年   435篇
  2020年   338篇
  2019年   354篇
  2018年   327篇
  2017年   228篇
  2016年   174篇
  2015年   259篇
  2014年   460篇
  2013年   451篇
  2012年   365篇
  2011年   357篇
  2010年   281篇
  2009年   236篇
  2008年   266篇
  2007年   218篇
  2006年   219篇
  2005年   198篇
  2004年   137篇
  2003年   119篇
  2002年   88篇
  2001年   79篇
  2000年   51篇
  1999年   55篇
  1998年   39篇
  1997年   32篇
  1996年   26篇
  1995年   30篇
  1994年   29篇
  1993年   14篇
  1992年   10篇
  1991年   11篇
  1990年   13篇
  1989年   8篇
  1988年   8篇
  1987年   3篇
  1986年   3篇
  1985年   7篇
  1984年   3篇
  1983年   1篇
  1982年   4篇
  1981年   1篇
  1980年   1篇
  1979年   3篇
  1978年   1篇
  1977年   1篇
  1974年   1篇
  1973年   2篇
排序方式: 共有6360条查询结果,搜索用时 15 毫秒
101.
随着临床试验在国内日渐频繁,知情同意权作为受试者的一项权利已经得到普遍认同,现在医患双方都比较注重诊疗实践中一般的知情同意,而对临床试验中受试者这一特殊群体的"知情同意"没有引起足够的重视,导致在实践中这项权利常被侵犯,为医疗纠纷埋下了隐患。医院作为临床试验的必经场所,理应肩负起保护受试者权益的重任,文章从医院管理着手通过分析目前受试者知情同意权的保护现状进而探讨保护措施。  相似文献   
102.
103.
104.
105.
106.

Purpose

To assess short- and long-term mortality and rebleeding with endoscopic cyanoacrylate (EC) versus balloon-occluded retrograde transvenous obliteration (BRTO).

Materials and Methods

A retrospective cohort comparison was conducted of 90 EC patients and 71 BRTO patients from 1997 through 2015 with portal hypertension who presented due to endoscopically confirmed bleeding cardiofundal gastric varices. Patients underwent either endoscopic intra-varix injection of 4-carbon-n-butyl-2-cyanoacrylate or sclerosis with sodium tetradecyl sulfate with balloon occlusion for primary variceal treatment.

Results

Seventy-one BRTO patients and 90 EC patients, of whom 89% had cirrhosis and 35% were women, were included, with a respective average Model for End-Stage Liver Disease (MELD) score of 13.4 and 14.4, respectively. Mortality at 6 weeks was 14.4% for EC patients and 13.1% for BRTO patients (Kaplan-Meier/Wilcoxon, P = .85). No long-term mortality difference was observed (Cox hazard ratio [HR] = 0.89, P = .64). Also, 5.1% of EC patients and 3.5% of BRTO patients (Kaplan-Meier/Wilcoxon, P = .62) rebled at 6 weeks, but at 1 year, 22.0% of EC patients and 3.5% of BRTO patients had rebled (Kaplan-Meier/Wilcoxon, P < .01). Lower rates of long-term rebleeding were found with BRTO (Cox HR = 0.25, P = .03). No difference was seen in the rate of new portal hypertensive complications (Cox HR = 1.21, P = .464). However, 16/71 patients who underwent BRTO had simultaneous transjugular intrahepatic portosystemic shunt. Age, sex, MELD score, and presence of cirrhosis were the primary predictors of mortality. One death in the EC group and 5 deaths in the BRTO group were deemed to be procedurally related (chi-square, P = .088).

Conclusions

BRTO is associated with a lower rate of rebleeding but no change in mortality.  相似文献   
107.
108.
109.
ObjectiveTo develop an algorithm for building longitudinal medication dose datasets using information extracted from clinical notes in electronic health records (EHRs).Materials and MethodsWe developed an algorithm that converts medication information extracted using natural language processing (NLP) into a usable format and builds longitudinal medication dose datasets. We evaluated the algorithm on 2 medications extracted from clinical notes of Vanderbilt’s EHR and externally validated the algorithm using clinical notes from the MIMIC-III clinical care database.ResultsFor the evaluation using Vanderbilt’s EHR data, the performance of our algorithm was excellent; F1-measures were ≥0.98 for both dose intake and daily dose. For the external validation using MIMIC-III, the algorithm achieved F1-measures ≥0.85 for dose intake and ≥0.82 for daily dose.DiscussionOur algorithm addresses the challenge of building longitudinal medication dose data using information extracted from clinical notes. Overall performance was excellent, but the algorithm can perform poorly when incorrect information is extracted by NLP systems. Although it performed reasonably well when applied to the external data source, its performance was worse due to differences in the way the drug information was written. The algorithm is implemented in the R package, “EHR,” and the extracted data from Vanderbilt’s EHRs along with the gold standards are provided so that users can reproduce the results and help improve the algorithm.ConclusionOur algorithm for building longitudinal dose data provides a straightforward way to use EHR data for medication-based studies. The external validation results suggest its potential for applicability to other systems.  相似文献   
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号